von Heyden B, Donatucci C F, Kaula N, Lue T F
Department of Urology, University of California School of Medicine, San Francisco.
J Urol. 1993 May;149(5 Pt 2):1288-90. doi: 10.1016/s0022-5347(17)36370-x.
We performed a retrospective analysis of 101 impotent patients using intracavernous self-injections as primary therapy for vasculogenic impotence. A total of 70 patients used an average of 5.58 micrograms prostaglandin E1 (95% confidence interval 4.83 to 6.34 micrograms) as a single agent, and 31 injected 0.40 ml. (95% confidence interval 0.342 to 0.457 ml.) of a combination of papaverine (12 mg./ml.), phentolamine (1 mg./ml.) and prostaglandin E1 (9 micrograms/ml.). We describe the procedure to establish the dosage for home use and discuss the implications of the low dosages relative to previous reports.
我们对101例阳痿患者进行了回顾性分析，这些患者将海绵体内自我注射作为血管性阳痿的主要治疗方法。共有70例患者平均使用5.58微克前列腺素E1（95%置信区间为4.83至6.34微克）作为单一药物，31例患者注射了0.40毫升（95%置信区间为0.342至0.457毫升）的罂粟碱（12毫克/毫升）、酚妥拉明（1毫克/毫升）和前列腺素E1（9微克/毫升）的混合液。我们描述了确定家庭使用剂量的方法，并讨论了与先前报告相比低剂量的影响。
